Comparing overall survival of patients with metastatic uveal melanoma by sequence of Tebentafusp versus combination immune checkpoint inhibitors.

被引：0
|
作者：
Shikdar, Sufana
Day, Silas
Ikeguchi, Alexandra
Ying, Yuan
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[2] Univ Oklahoma, Med Ctr, Oklahoma City, OK USA
[3] Stephenson Canc Ctr, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21505
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
    Piulats, J. M.
    Watkins, C.
    Costa-Garcia, M.
    del Carpio, L.
    Piperno-Neumann, S.
    Rutkowski, P.
    Hassel, J. C.
    Espinosa, E.
    de la Cruz-Merino, L.
    Ochsenreither, S.
    Shoushtari, A. N.
    Orloff, M.
    Salama, A. K. S.
    Goodall, H. M.
    Baurain, J. -F.
    Nathan, P.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 317 - 326
  • [32] Surgery in patients with metastatic melanoma treated with immune checkpoint inhibitors
    Janssen, Josephine C.
    Huibers, Anne E.
    Grunhagen, Dirk J.
    Bagge, Roger Olofsson
    SCANDINAVIAN JOURNAL OF SURGERY, 2025,
  • [33] Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
    Orloff, M.
    Watkins, C.
    Carvajal, R. D.
    Shoushtari, A. N.
    Sacco, J. J.
    Schlaak, M.
    Gama, J.
    Butler, M. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S678 - S678
  • [34] Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma
    Sullivan, Ryan
    Collins, Laura
    Rodrigues, Manuel
    Nathan, Paul
    Hassel, Jessica C.
    Dummer, Reinhard
    Kirkwood, John
    Rutkowski, Piotr
    Baurain, Jean-Francois
    Butler, Marcus O.
    Schlaak, Max
    Ochsenreither, Sebastian
    Abdullah, Shaad E.
    Holland, Chris
    Ranade, Koustubh
    Shoushtari, Alexander N.
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors
    Tonneau, Marion
    Nolin-Lapalme, Alexis
    Kazandjian, Suzanne
    Auclin, Edouard
    Panasci, Justin
    Benlaifaoui, Myriam
    Ponce, Mayra
    Al-Saleh, Afnan
    Belkaid, Wiam
    Naimi, Sabrine
    Mihalcioiu, Catalin
    Watson, Ian
    Bouin, Mickael
    Miller, Wilson
    Hudson, Marie
    Wong, Matthew K.
    Pezo, Rossanna C.
    Turcotte, Simon
    Belanger, Karl
    Jamal, Rahima
    Oster, Paul
    Velin, Dominique
    Richard, Corentin
    Messaoudene, Meriem
    Elkrief, Arielle
    Routy, Bertrand
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [36] Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
    Shoushtari, A. N.
    Collins, L.
    Espinosa, E.
    Sethi, H.
    Stanhope, S.
    Abdullah, S.
    Ikeguchi, A.
    Ranade, K.
    Hamid, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S1210 - S1210
  • [37] Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors
    Adhikari, Arjab
    Sapkota, Supriya
    Gogia, Sopiko
    Ojbindra, K. C.
    CANCER EPIDEMIOLOGY, 2024, 92
  • [38] Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment
    Petzold, Anne
    Steeb, Theresa
    Wessely, Anja
    Koch, Elias A. T.
    Vera, Julio
    Berking, Carola
    Heppt, Markus, V
    CANCER TREATMENT REVIEWS, 2023, 115
  • [39] Hyperprogressive disease in patients with metastatic genitourinary tumors treated with immune checkpoint inhibitors.
    Suarez, Cristina
    Morales-Barrera, Rafael
    Garcia-Ruiz, Alonso
    Gonzalez, Macarena
    Ligero, Marta
    Valverde, Claudia
    Serrano, Cesar
    Mateo, Joaquin
    Perez-Lopez, Raquel
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [40] Low baseline macrophage to T cell ratio is predictive of overall survival with tebentafusp in a phase 3 trial in metastatic uveal melanoma.
    Piperno-Neumann, Sophie
    Stanhope, Sarah
    Britton-Rivet, Camille
    Bischetti, Simone
    Abdullah, Shaad
    Collins, Laura
    Ranade, Koustubh
    Leach, Emma
    Rutkowski, Piotr
    CANCER RESEARCH, 2022, 82 (12)
12345